Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Cynosure Agrees to Buy Palomar in $294 Million Laser Deal

Cynosure Inc., which makes lasers for medical and cosmetic treatments, agreed to acquire competitor Palomar Medical Technologies Inc. for $294 million in cash and shares.

The deal will give investors of Burlington, Massachusetts-based Palomar $13.65 a share, half in cash and half in stock of Westford, Massachusetts-based Cynosure, the companies said in a statement today. That represents an 8.2 percent premium to the March 15 closing price of Palomar shares.

Cynosure will have more than 20,000 cosmetic laser systems installed in 100 countries after the acquisition is complete, the companies said. Often located in doctors’ offices, the devices are used for hair and tattoo removal, scar treatment, and laser liposuction, according to the companies’ websites.

“Combining with Palomar complements our product portfolio and customer base, adding new product and service revenues, strengthening our global distribution network, creating new cross-selling opportunities and enhancing our intellectual property position,” Cynosure Chief Executive Officer Michael Davin said in the statement.

The acquisition should be completed in the third quarter and lead to $8 million to $10 million in cost savings, the company said.

Cynosure fell 4.8 percent to $27.10 at the close in New York. Palomar shares gained 4.4 percent to $13.17.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.